Validation of miRNA biomarkers for the early diagnosis of lung cancer

• Conditions: ung cancer; C34; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00017455
• Lead Sponsor: Hummingbird Diagnostics GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-23
• Study Completion: 2020-01-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting stopped after recruiting started
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. Male or female patient with suspected pneumological pathology finding
2. Signed consent
3. Patient is at least 18 years old

Exclusion Criteria

Patient is younger than 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Demonstration of the sensitivity and specificity of the HBDx miRNA signature for the diagnosis of NSCLC using microarray technology.

Secondary Outcome Measures

Name	Time	Method
Demonstrate the evidence of therapeutic success in patients with NSCLC also at the miRNA level using HBDx microarray technology